Showing results (131-140 of 946) with videos related to
Sort By:
Pageof 95
Psychopharmacology|January 1, 1991
Drugs acting at D-1 and D-2 dopamine receptors induce identical purposeless chewing in rats which can be differentiated by cholinergic manipulationP Collins, C L Broekkamp, P Jenner, et al.Neuropharmacology|April 1, 1987
In vitro characterisation of dopamine receptors in the superior colliculus of the ratM E Weller, S Rose, P Jenner, et al.Movement Disorders : Official Journal of the Movement Disorder Society|April 16, 1998
P450 enzymes and Parkinson's disease: the story so farA G Riedl, P M Watts, P Jenner, et al.Biochemical Pharmacology|June 1, 1984
Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neuronesS Boyce, E Kelly, C Reavill, et al.Neuroscience Letters|October 12, 1992
Striatal neuropeptide levels in Parkinson's disease patientsA Fernandez, M L de Ceballos, P Jenner, et al.Psychopharmacologia|January 1, 1975
Pharmacological evidence for cerebral dopamine receptor blockade by metoclopramide in rodentsA Dolphin, P Jenner, C D Marsden, et al.Experimental Brain Research|January 1, 1986
Effects of somatostatin on dopamine sensitive adenylate cyclase activity in the caudate-putamen of the ratA Moser, C Reavill, P Jenner, et al.Biochemical Pharmacology|September 1, 1983
Persistent increase in striatal dopamine stimulated adenylate cyclase activity persists for more than 6 months but disappears after 1 year following withdrawal from 18 months cis-flupenthixol intakeK Murugaiah, S Fleminger, A Theodorou, et al.European Journal of Pharmacology|December 30, 1996
Dopamine D3 receptors are not involved in the induction of c-fos mRNA by neuroleptic drugs: comparison of the dopamine D3 receptor antagonist GR103691 with typical and atypical neurolepticsM J Hurley, C M Stubbs, P Jenner, et al.Annals of the New York Academy of Sciences|June 15, 1996
Oxidative stress and Parkinson's diseaseA D Owen, A H Schapira, P Jenner, et al.Pageof 95